{
 "disease": "osteosarcoma",
 "label": "Osteosarcoma",
 "url": "https://usebiotransfer.org/disease/osteosarcoma/",
 "built": "2026-09-16",
 "facts_hash": {
  "answers": "8fc4ed517604",
  "targets": "efb8a1c12923"
 },
 "sources": {
  "targets": "Open Targets Platform GraphQL API v4",
  "trials": "ClinicalTrials.gov API v2"
 },
 "retrieved": {
  "targets": "2026-09-16",
  "trials": "2026-09-16"
 },
 "query": {
  "endpoint": "https://clinicaltrials.gov/api/v2/studies",
  "shape": "query.cond=<disease>&query.intr=<term>&pageSize=200",
  "active_statuses": [
   "ACTIVE_NOT_RECRUITING",
   "ENROLLING_BY_INVITATION",
   "NOT_YET_RECRUITING",
   "RECRUITING"
  ],
  "dedup": "by NCT id across synonyms",
  "study_types": "interventional counted in headline; observational reported separately",
  "known_floor": "trials naming an antigen only by product code are not retrieved by an intervention-name search"
 },
 "targets": [
  {
   "symbol": "TP53",
   "ensembl": "ENSG00000141510",
   "n_drug_entries": 9,
   "n_distinct_drugs": 8,
   "drugs": {
    "ALRIZOMADLIN": "PHASE_2",
    "CENERSEN": "PHASE_2",
    "CONTUSUGENE LADENOVEC": "PHASE_3",
    "EPRENETAPOPT": "PHASE_3",
    "IDASANUTLIN": "PHASE_3",
    "NAVTEMADLIN": "PHASE_3",
    "SIREMADLIN": "PHASE_2",
    "TEPRASIRAN": "PHASE_3"
   },
   "approved": [],
   "n_approved": 0,
   "approved_for": {},
   "tractability": [
    {
     "modality": "SM",
     "bucket": "Advanced Clinical"
    },
    {
     "modality": "SM",
     "bucket": "Structure with Ligand"
    },
    {
     "modality": "SM",
     "bucket": "High-Quality Ligand"
    },
    {
     "modality": "SM",
     "bucket": "Med-Quality Pocket"
    },
    {
     "modality": "SM",
     "bucket": "Druggable Family"
    },
    {
     "modality": "PR",
     "bucket": "UniProt Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Database Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Small Molecule Binder"
    },
    {
     "modality": "OC",
     "bucket": "Advanced Clinical"
    }
   ]
  },
  {
   "symbol": "RB1",
   "ensembl": "ENSG00000139687",
   "n_drug_entries": 0,
   "n_distinct_drugs": 0,
   "drugs": {},
   "approved": [],
   "n_approved": 0,
   "approved_for": {},
   "tractability": [
    {
     "modality": "SM",
     "bucket": "High-Quality Ligand"
    },
    {
     "modality": "SM",
     "bucket": "Med-Quality Pocket"
    },
    {
     "modality": "SM",
     "bucket": "Druggable Family"
    },
    {
     "modality": "PR",
     "bucket": "Database Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Half-life Data"
    },
    {
     "modality": "PR",
     "bucket": "Small Molecule Binder"
    }
   ]
  },
  {
   "symbol": "MYC",
   "ensembl": "ENSG00000136997",
   "n_drug_entries": 0,
   "n_distinct_drugs": 0,
   "drugs": {},
   "approved": [],
   "n_approved": 0,
   "approved_for": {},
   "tractability": [
    {
     "modality": "SM",
     "bucket": "Structure with Ligand"
    },
    {
     "modality": "SM",
     "bucket": "High-Quality Ligand"
    },
    {
     "modality": "PR",
     "bucket": "UniProt Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Database Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Small Molecule Binder"
    }
   ]
  },
  {
   "symbol": "CDK4",
   "ensembl": "ENSG00000135446",
   "n_drug_entries": 17,
   "n_distinct_drugs": 15,
   "drugs": {
    "ABEMACICLIB": "APPROVAL",
    "AG-24322": "PHASE_1",
    "ALVOCIDIB": "PHASE_3",
    "AT-7519": "PHASE_2",
    "AZD-5438": "PHASE_1",
    "MILCICLIB": "PHASE_2",
    "PALBOCICLIB": "APPROVAL",
    "PHA-793887": "PHASE_1",
    "RG-547": "PHASE_1",
    "RGB-286638": "PHASE_1",
    "RIBOCICLIB": "APPROVAL",
    "RONICICLIB": "PHASE_2",
    "TRILACICLIB": "APPROVAL",
    "UCN-01": "PHASE_2",
    "VORUCICLIB": "PHASE_1"
   },
   "approved": [
    "ABEMACICLIB",
    "PALBOCICLIB",
    "RIBOCICLIB",
    "TRILACICLIB"
   ],
   "n_approved": 4,
   "approved_for": {
    "ABEMACICLIB": [
     "breast cancer",
     "breast neoplasm",
     "breast carcinoma"
    ],
    "PALBOCICLIB": [
     "breast cancer",
     "breast carcinoma",
     "breast neoplasm"
    ],
    "RIBOCICLIB": [
     "breast cancer",
     "breast neoplasm",
     "breast carcinoma"
    ],
    "TRILACICLIB": [
     "small cell lung carcinoma",
     "myelosuppression"
    ]
   },
   "tractability": [
    {
     "modality": "SM",
     "bucket": "Approved Drug"
    },
    {
     "modality": "SM",
     "bucket": "Structure with Ligand"
    },
    {
     "modality": "SM",
     "bucket": "High-Quality Ligand"
    },
    {
     "modality": "SM",
     "bucket": "High-Quality Pocket"
    },
    {
     "modality": "SM",
     "bucket": "Druggable Family"
    },
    {
     "modality": "PR",
     "bucket": "Literature"
    },
    {
     "modality": "PR",
     "bucket": "Database Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Half-life Data"
    },
    {
     "modality": "PR",
     "bucket": "Small Molecule Binder"
    }
   ]
  },
  {
   "symbol": "MDM2",
   "ensembl": "ENSG00000135679",
   "n_drug_entries": 4,
   "n_distinct_drugs": 4,
   "drugs": {
    "ALRIZOMADLIN": "PHASE_2",
    "IDASANUTLIN": "PHASE_3",
    "NAVTEMADLIN": "PHASE_3",
    "SIREMADLIN": "PHASE_2"
   },
   "approved": [],
   "n_approved": 0,
   "approved_for": {},
   "tractability": [
    {
     "modality": "SM",
     "bucket": "Advanced Clinical"
    },
    {
     "modality": "SM",
     "bucket": "Structure with Ligand"
    },
    {
     "modality": "SM",
     "bucket": "High-Quality Ligand"
    },
    {
     "modality": "SM",
     "bucket": "High-Quality Pocket"
    },
    {
     "modality": "SM",
     "bucket": "Druggable Family"
    },
    {
     "modality": "AB",
     "bucket": "GO CC high conf"
    },
    {
     "modality": "PR",
     "bucket": "Literature"
    },
    {
     "modality": "PR",
     "bucket": "UniProt Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Database Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Small Molecule Binder"
    }
   ]
  },
  {
   "symbol": "VEGFA",
   "ensembl": "ENSG00000112715",
   "n_drug_entries": 14,
   "n_distinct_drugs": 13,
   "drugs": {
    "ABICIPAR PEGOL": "APPROVAL",
    "AFLIBERCEPT": "APPROVAL",
    "BEVACIZUMAB": "APPROVAL",
    "BEVACIZUMAB GAMMA": "APPROVAL",
    "BEVASIRANIB": "PHASE_3",
    "BROLUCIZUMAB": "APPROVAL",
    "CONBERCEPT": "PHASE_3",
    "FARICIMAB": "APPROVAL",
    "MUPARFOSTAT": "PHASE_3",
    "PEGAPTANIB": "APPROVAL",
    "PEGAPTANIB OCTASODIUM": "PHASE_3",
    "RANIBIZUMAB": "APPROVAL",
    "VANUCIZUMAB": "PHASE_2"
   },
   "approved": [
    "ABICIPAR PEGOL",
    "AFLIBERCEPT",
    "BEVACIZUMAB",
    "BEVACIZUMAB GAMMA",
    "BROLUCIZUMAB",
    "FARICIMAB",
    "PEGAPTANIB",
    "RANIBIZUMAB"
   ],
   "n_approved": 8,
   "approved_for": {
    "ABICIPAR PEGOL": [
     "ocular vascular disorder"
    ],
    "AFLIBERCEPT": [
     "macular degeneration",
     "retinal vein occlusion",
     "colorectal cancer",
     "choroidal neovascularization",
     "diabetic macular edema",
     "myopia",
     "edema",
     "metastatic colorectal cancer",
     "macular retinal edema",
     "macrovascular complications of diabetes",
     "wet macular degeneration",
     "colorectal neoplasm",
     "pathological myopia",
     "diabetic retinopathy",
     "colorectal adenocarcinoma",
     "ocular vascular disorder"
    ],
    "BEVACIZUMAB": [
     "colorectal cancer",
     "non-small cell squamous lung carcinoma",
     "breast cancer",
     "cervical cancer",
     "non-small cell lung carcinoma",
     "colorectal adenocarcinoma",
     "renal cell carcinoma",
     "colonic neoplasm",
     "glioblastoma",
     "metastatic colorectal cancer",
     "breast neoplasm",
     "peritoneal neoplasm",
     "colorectal neoplasm",
     "fallopian tube neoplasm",
     "ovarian neoplasm",
     "fallopian tube carcinoma",
     "ocular vascular disorder"
    ],
    "BEVACIZUMAB GAMMA": [
     "wet macular degeneration"
    ],
    "BROLUCIZUMAB": [
     "macular degeneration",
     "wet macular degeneration",
     "ocular vascular disorder"
    ],
    "FARICIMAB": [
     "diabetic macular edema",
     "wet macular degeneration",
     "macular retinal edema",
     "cystoid macular edema",
     "ocular vascular disorder"
    ],
    "PEGAPTANIB": [
     "wet macular degeneration",
     "macular degeneration"
    ],
    "RANIBIZUMAB": [
     "macular degeneration",
     "hereditary hemorrhagic telangiectasia",
     "macular retinal edema",
     "diabetic retinopathy",
     "wet macular degeneration",
     "macrovascular complications of diabetes",
     "myopia",
     "pathological myopia",
     "choroidal neovascularization",
     "retinal vein occlusion",
     "ocular vascular disorder"
    ]
   },
   "tractability": [
    {
     "modality": "SM",
     "bucket": "Structure with Ligand"
    },
    {
     "modality": "SM",
     "bucket": "High-Quality Ligand"
    },
    {
     "modality": "SM",
     "bucket": "Med-Quality Pocket"
    },
    {
     "modality": "AB",
     "bucket": "Approved Drug"
    },
    {
     "modality": "AB",
     "bucket": "UniProt loc high conf"
    },
    {
     "modality": "AB",
     "bucket": "GO CC high conf"
    },
    {
     "modality": "AB",
     "bucket": "UniProt loc med conf"
    },
    {
     "modality": "PR",
     "bucket": "Small Molecule Binder"
    },
    {
     "modality": "OC",
     "bucket": "Approved Drug"
    }
   ]
  },
  {
   "symbol": "KDR",
   "ensembl": "ENSG00000128052",
   "n_drug_entries": 75,
   "n_distinct_drugs": 70,
   "drugs": {
    "4SC-203": "PHASE_1",
    "AEE-788": "PHASE_1_2",
    "ALACIZUMAB PEGOL": "PHASE_2",
    "ALTIRATINIB": "PHASE_1",
    "AXITINIB": "APPROVAL",
    "BFH-772": "PHASE_2",
    "BMS-690514": "PHASE_2",
    "BMS-817378": "PHASE_1",
    "BRIVANIB": "PHASE_3",
    "BRIVANIB ALANINATE": "PHASE_3",
    "CABOZANTINIB": "APPROVAL",
    "CABOZANTINIB S-MALATE": "APPROVAL",
    "CATEQUENTINIB": "PHASE_3",
    "CEDIRANIB": "APPROVAL",
    "CEP-11981": "PHASE_2",
    "CEP-5214": "UNKNOWN",
    "CM-082": "PHASE_2",
    "CYC-116": "PHASE_1",
    "DOVITINIB": "PHASE_3",
    "ENMD-2076": "PHASE_2",
    "ENMD-981693": "PHASE_2",
    "FAMITINIB": "PHASE_3",
    "FORETINIB": "PHASE_2",
    "FRUQUINTINIB": "APPROVAL",
    "GLESATINIB": "PHASE_2",
    "GOLVATINIB": "PHASE_1_2",
    "HENATINIB": "PHASE_1",
    "IBCASERTIB": "PHASE_3",
    "ILORASERTIB": "PHASE_2",
    "IMC-1C11": "PHASE_1",
    "JI-101": "PHASE_2",
    "KRN-633": "PHASE_1",
    "LENVATINIB": "APPROVAL",
    "LINIFANIB": "PHASE_3",
    "LUCITANIB": "PHASE_3",
    "MIDOSTAURIN": "APPROVAL",
    "MOTESANIB": "PHASE_3",
    "NINGETINIB": "PHASE_2",
    "NINTEDANIB": "APPROVAL",
    "NINTEDANIB ESYLATE": "APPROVAL",
    "OLINVACIMAB": "PHASE_2",
    "ORANTINIB": "PHASE_3",
    "OSI-632": "PHASE_2",
    "OSI-930": "PHASE_1",
    "PAZOPANIB": "APPROVAL",
    "PEGDINETANIB": "PHASE_2",
    "PF-00337210": "PHASE_1",
    "RAF-265": "PHASE_2",
    "RAMUCIRUMAB": "APPROVAL",
    "REGORAFENIB": "APPROVAL",
    "RG-1530": "PHASE_1",
    "RIVOCERANIB": "APPROVAL",
    "SEMAXANIB": "PHASE_3",
    "SORAFENIB": "APPROVAL",
    "SU-014813": "PHASE_2",
    "SUNITINIB": "APPROVAL",
    "SUNITINIB MALATE": "APPROVAL",
    "SURUFATINIB": "APPROVAL",
    "TAK-593": "PHASE_1",
    "TAS-115": "PHASE_1",
    "TELATINIB": "PHASE_2",
    "TELBERMIN": "PHASE_2",
    "TG100-801": "PHASE_2",
    "TIVOZANIB": "APPROVAL",
    "VANDETANIB": "APPROVAL",
    "VATALANIB": "PHASE_3",
    "X-82": "PHASE_2",
    "XL-820": "PHASE_2",
    "XL-999": "PHASE_2",
    "ZD-4190": "UNKNOWN"
   },
   "approved": [
    "AXITINIB",
    "CABOZANTINIB",
    "CABOZANTINIB S-MALATE",
    "CEDIRANIB",
    "FRUQUINTINIB",
    "LENVATINIB",
    "MIDOSTAURIN",
    "NINTEDANIB",
    "NINTEDANIB ESYLATE",
    "PAZOPANIB",
    "RAMUCIRUMAB",
    "REGORAFENIB",
    "RIVOCERANIB",
    "SORAFENIB",
    "SUNITINIB",
    "SUNITINIB MALATE",
    "SURUFATINIB",
    "TIVOZANIB",
    "VANDETANIB"
   ],
   "n_approved": 19,
   "approved_for": {
    "AXITINIB": [
     "renal cell carcinoma"
    ],
    "CABOZANTINIB": [
     "thyroid cancer",
     "thyroid tumor",
     "hepatocellular carcinoma",
     "renal cell carcinoma",
     "medullary thyroid gland carcinoma"
    ],
    "CABOZANTINIB S-MALATE": [
     "thyroid gland carcinoma",
     "renal cell carcinoma"
    ],
    "CEDIRANIB": [],
    "FRUQUINTINIB": [
     "colorectal cancer",
     "colorectal neoplasm"
    ],
    "LENVATINIB": [
     "thyroid cancer",
     "thyroid tumor",
     "renal cell carcinoma",
     "differentiated thyroid carcinoma",
     "thyroid gland carcinoma"
    ],
    "MIDOSTAURIN": [
     "mast cell leukemia",
     "mastocytosis",
     "acute myeloid leukemia by FAB classification",
     "systemic mastocytosis",
     "acute myeloid leukemia"
    ],
    "NINTEDANIB": [
     "idiopathic pulmonary fibrosis",
     "colorectal cancer",
     "interstitial lung disease",
     "systemic sclerosis",
     "pulmonary fibrosis"
    ],
    "NINTEDANIB ESYLATE": [
     "idiopathic pulmonary fibrosis",
     "systemic sclerosis",
     "non-small cell lung carcinoma",
     "Interstitial pneumonitis"
    ],
    "PAZOPANIB": [
     "soft tissue sarcoma",
     "renal cell carcinoma",
     "sarcoma"
    ],
    "RAMUCIRUMAB": [
     "gastric cancer",
     "non-small cell lung carcinoma",
     "gastric adenocarcinoma",
     "gastric neoplasm",
     "gastroesophageal junction adenocarcinoma"
    ],
    "REGORAFENIB": [
     "colorectal cancer",
     "metastatic colorectal cancer",
     "colorectal neoplasm"
    ],
    "RIVOCERANIB": [
     "breast cancer"
    ],
    "SORAFENIB": [
     "renal cell carcinoma",
     "thyroid gland carcinoma",
     "hepatocellular carcinoma"
    ],
    "SUNITINIB": [
     "gastrointestinal stromal tumor",
     "renal cell carcinoma",
     "neuroendocrine neoplasm"
    ],
    "SUNITINIB MALATE": [
     "renal cell carcinoma",
     "gastrointestinal stromal tumor",
     "neuroendocrine neoplasm"
    ],
    "SURUFATINIB": [],
    "TIVOZANIB": [
     "renal cell carcinoma"
    ],
    "VANDETANIB": [
     "thyroid gland carcinoma",
     "medullary thyroid gland carcinoma",
     "thyroid tumor"
    ]
   },
   "tractability": [
    {
     "modality": "SM",
     "bucket": "Approved Drug"
    },
    {
     "modality": "SM",
     "bucket": "Structure with Ligand"
    },
    {
     "modality": "SM",
     "bucket": "High-Quality Ligand"
    },
    {
     "modality": "SM",
     "bucket": "High-Quality Pocket"
    },
    {
     "modality": "SM",
     "bucket": "Druggable Family"
    },
    {
     "modality": "AB",
     "bucket": "Approved Drug"
    },
    {
     "modality": "AB",
     "bucket": "UniProt loc high conf"
    },
    {
     "modality": "AB",
     "bucket": "GO CC high conf"
    },
    {
     "modality": "AB",
     "bucket": "UniProt loc med conf"
    },
    {
     "modality": "AB",
     "bucket": "UniProt SigP or TMHMM"
    },
    {
     "modality": "PR",
     "bucket": "UniProt Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Database Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Small Molecule Binder"
    },
    {
     "modality": "OC",
     "bucket": "Advanced Clinical"
    }
   ]
  },
  {
   "symbol": "ERBB2",
   "ensembl": "ENSG00000141736",
   "n_drug_entries": 48,
   "n_distinct_drugs": 45,
   "drugs": {
    "AC-480": "PHASE_2",
    "AEE-788": "PHASE_1_2",
    "AFATINIB": "APPROVAL",
    "AFATINIB DIMALEATE": "APPROVAL",
    "ALLITINIB": "PHASE_1",
    "ANVATABART OPADOTIN": "PHASE_2_3",
    "AV-412": "PHASE_1",
    "BMS-690514": "PHASE_2",
    "CANERTINIB": "PHASE_2",
    "CP-724714": "PHASE_2",
    "CUDC-101": "PHASE_1",
    "DACOMITINIB": "APPROVAL",
    "DISITAMAB VEDOTIN": "PHASE_3",
    "ERTUMAXOMAB": "PHASE_2",
    "GANCOTAMAB": "PHASE_2_3",
    "HEMAY-022": "PHASE_3",
    "JNJ-26483327": "PHASE_1",
    "KBP5209": "PHASE_1",
    "KN-026": "PHASE_3",
    "LAPATINIB": "APPROVAL",
    "LAPATINIB DITOSYLATE": "APPROVAL",
    "MARGETUXIMAB": "APPROVAL",
    "MASOPROCOL": "APPROVAL",
    "MM-111": "PHASE_2",
    "MUBRITINIB": "PHASE_1",
    "NERATINIB": "APPROVAL",
    "PERTUZUMAB": "APPROVAL",
    "POZIOTINIB": "PHASE_3",
    "PYROTINIB": "PHASE_3",
    "S-222611": "PHASE_1",
    "SAPITINIB": "PHASE_2",
    "TAK-285": "PHASE_1",
    "TARLOXOTINIB": "PHASE_2",
    "TESEVATINIB": "PHASE_3",
    "TRASTUZUMAB": "APPROVAL",
    "TRASTUZUMAB BOTIDOTIN": "PHASE_3",
    "TRASTUZUMAB DERUXTECAN": "APPROVAL",
    "TRASTUZUMAB DUOCARMAZINE": "APPROVAL",
    "TRASTUZUMAB EMTANSINE": "APPROVAL",
    "TUCATINIB": "APPROVAL",
    "TUXOBERTINIB": "PHASE_1_2",
    "VANDETANIB": "APPROVAL",
    "VARLITINIB": "PHASE_2_3",
    "ZANIDATAMAB": "APPROVAL",
    "ZENOCUTUZUMAB": "APPROVAL"
   },
   "approved": [
    "AFATINIB",
    "AFATINIB DIMALEATE",
    "DACOMITINIB",
    "LAPATINIB",
    "LAPATINIB DITOSYLATE",
    "MARGETUXIMAB",
    "MASOPROCOL",
    "NERATINIB",
    "PERTUZUMAB",
    "TRASTUZUMAB",
    "TRASTUZUMAB DERUXTECAN",
    "TRASTUZUMAB DUOCARMAZINE",
    "TRASTUZUMAB EMTANSINE",
    "TUCATINIB",
    "VANDETANIB",
    "ZANIDATAMAB",
    "ZENOCUTUZUMAB"
   ],
   "n_approved": 17,
   "approved_for": {
    "AFATINIB": [
     "non-small cell lung carcinoma"
    ],
    "AFATINIB DIMALEATE": [
     "non-small cell lung carcinoma"
    ],
    "DACOMITINIB": [
     "non-small cell lung carcinoma"
    ],
    "LAPATINIB": [
     "breast cancer"
    ],
    "LAPATINIB DITOSYLATE": [
     "breast cancer",
     "breast neoplasm",
     "breast carcinoma"
    ],
    "MARGETUXIMAB": [
     "HER2 positive breast carcinoma",
     "breast cancer"
    ],
    "MASOPROCOL": [
     "prostate cancer"
    ],
    "NERATINIB": [
     "breast cancer",
     "breast neoplasm",
     "breast carcinoma"
    ],
    "PERTUZUMAB": [
     "breast cancer",
     "breast carcinoma",
     "breast neoplasm"
    ],
    "TRASTUZUMAB": [
     "breast cancer",
     "breast carcinoma",
     "gastric cancer",
     "gastric neoplasm",
     "breast neoplasm"
    ],
    "TRASTUZUMAB DERUXTECAN": [
     "breast cancer",
     "HER2 positive breast carcinoma",
     "breast neoplasm"
    ],
    "TRASTUZUMAB DUOCARMAZINE": [],
    "TRASTUZUMAB EMTANSINE": [
     "breast cancer",
     "breast carcinoma",
     "breast neoplasm"
    ],
    "TUCATINIB": [
     "HER2 positive breast carcinoma",
     "metastasis",
     "breast neoplasm",
     "breast cancer",
     "colorectal carcinoma",
     "breast carcinoma"
    ],
    "VANDETANIB": [
     "thyroid gland carcinoma",
     "medullary thyroid gland carcinoma",
     "thyroid tumor"
    ],
    "ZANIDATAMAB": [
     "biliary tract neoplasm"
    ],
    "ZENOCUTUZUMAB": [
     "non-small cell lung carcinoma",
     "pancreatic neoplasm"
    ]
   },
   "tractability": [
    {
     "modality": "SM",
     "bucket": "Approved Drug"
    },
    {
     "modality": "SM",
     "bucket": "Structure with Ligand"
    },
    {
     "modality": "SM",
     "bucket": "High-Quality Ligand"
    },
    {
     "modality": "SM",
     "bucket": "High-Quality Pocket"
    },
    {
     "modality": "SM",
     "bucket": "Druggable Family"
    },
    {
     "modality": "AB",
     "bucket": "Approved Drug"
    },
    {
     "modality": "AB",
     "bucket": "UniProt loc high conf"
    },
    {
     "modality": "AB",
     "bucket": "GO CC high conf"
    },
    {
     "modality": "AB",
     "bucket": "UniProt SigP or TMHMM"
    },
    {
     "modality": "AB",
     "bucket": "Human Protein Atlas loc"
    },
    {
     "modality": "PR",
     "bucket": "Literature"
    },
    {
     "modality": "PR",
     "bucket": "Database Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Half-life Data"
    },
    {
     "modality": "PR",
     "bucket": "Small Molecule Binder"
    },
    {
     "modality": "OC",
     "bucket": "Approved Drug"
    }
   ]
  },
  {
   "symbol": "IGF1R",
   "ensembl": "ENSG00000140443",
   "n_drug_entries": 20,
   "n_distinct_drugs": 20,
   "drugs": {
    "AEW-541": "PHASE_1",
    "AXL-1717": "PHASE_2",
    "BIIB-022": "PHASE_1",
    "BMS-754807": "PHASE_2",
    "CIXUTUMUMAB": "PHASE_2",
    "CONTELTINIB": "PHASE_1_2",
    "DALOTUZUMAB": "PHASE_2",
    "FIGITUMUMAB": "PHASE_3",
    "GANITUMAB": "PHASE_3",
    "ISTIRATUMAB": "PHASE_2",
    "KW-2450": "PHASE_1_2",
    "LINSITINIB": "PHASE_3",
    "MASOPROCOL": "APPROVAL",
    "MECASERMIN": "APPROVAL",
    "MECASERMIN RINFABATE": "UNKNOWN",
    "PL-225B": "PHASE_1",
    "ROBATUMUMAB": "PHASE_2",
    "TEPROTUMUMAB": "APPROVAL",
    "VELIGROTUG": "PHASE_3",
    "XL-228": "PHASE_1"
   },
   "approved": [
    "MASOPROCOL",
    "MECASERMIN",
    "TEPROTUMUMAB"
   ],
   "n_approved": 3,
   "approved_for": {
    "MASOPROCOL": [
     "prostate cancer"
    ],
    "MECASERMIN": [
     "Growth delay",
     "hypothyroidism",
     "Laron syndrome"
    ],
    "TEPROTUMUMAB": [
     "Graves ophthalmopathy",
     "Graves disease"
    ]
   },
   "tractability": [
    {
     "modality": "SM",
     "bucket": "Approved Drug"
    },
    {
     "modality": "SM",
     "bucket": "Structure with Ligand"
    },
    {
     "modality": "SM",
     "bucket": "High-Quality Ligand"
    },
    {
     "modality": "SM",
     "bucket": "High-Quality Pocket"
    },
    {
     "modality": "SM",
     "bucket": "Druggable Family"
    },
    {
     "modality": "AB",
     "bucket": "Approved Drug"
    },
    {
     "modality": "AB",
     "bucket": "UniProt loc high conf"
    },
    {
     "modality": "AB",
     "bucket": "GO CC high conf"
    },
    {
     "modality": "AB",
     "bucket": "UniProt SigP or TMHMM"
    },
    {
     "modality": "PR",
     "bucket": "Literature"
    },
    {
     "modality": "PR",
     "bucket": "UniProt Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Database Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Half-life Data"
    },
    {
     "modality": "PR",
     "bucket": "Small Molecule Binder"
    },
    {
     "modality": "OC",
     "bucket": "Approved Drug"
    }
   ]
  },
  {
   "symbol": "CD276",
   "ensembl": "ENSG00000103855",
   "n_drug_entries": 2,
   "n_distinct_drugs": 2,
   "drugs": {
    "8H9 131I": "PHASE_1",
    "ENOBLITUZUMAB": "PHASE_2_3"
   },
   "approved": [],
   "n_approved": 0,
   "approved_for": {},
   "tractability": [
    {
     "modality": "AB",
     "bucket": "Advanced Clinical"
    },
    {
     "modality": "AB",
     "bucket": "UniProt SigP or TMHMM"
    },
    {
     "modality": "PR",
     "bucket": "Database Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Half-life Data"
    }
   ]
  },
  {
   "symbol": "PTHLH",
   "ensembl": "ENSG00000087494",
   "n_drug_entries": 1,
   "n_distinct_drugs": 1,
   "drugs": {
    "CAL": "PHASE_1_2"
   },
   "approved": [],
   "n_approved": 0,
   "approved_for": {},
   "tractability": [
    {
     "modality": "SM",
     "bucket": "Structure with Ligand"
    },
    {
     "modality": "AB",
     "bucket": "Advanced Clinical"
    },
    {
     "modality": "AB",
     "bucket": "UniProt loc high conf"
    },
    {
     "modality": "AB",
     "bucket": "GO CC high conf"
    },
    {
     "modality": "AB",
     "bucket": "UniProt SigP or TMHMM"
    }
   ]
  },
  {
   "symbol": "CDK6",
   "ensembl": "ENSG00000105810",
   "n_drug_entries": 12,
   "n_distinct_drugs": 10,
   "drugs": {
    "ABEMACICLIB": "APPROVAL",
    "ALVOCIDIB": "PHASE_3",
    "AT-7519": "PHASE_2",
    "AZD-5438": "PHASE_1",
    "PALBOCICLIB": "APPROVAL",
    "PHA-793887": "PHASE_1",
    "RIBOCICLIB": "APPROVAL",
    "RONICICLIB": "PHASE_2",
    "TRILACICLIB": "APPROVAL",
    "UCN-01": "PHASE_2"
   },
   "approved": [
    "ABEMACICLIB",
    "PALBOCICLIB",
    "RIBOCICLIB",
    "TRILACICLIB"
   ],
   "n_approved": 4,
   "approved_for": {
    "ABEMACICLIB": [
     "breast cancer",
     "breast neoplasm",
     "breast carcinoma"
    ],
    "PALBOCICLIB": [
     "breast cancer",
     "breast carcinoma",
     "breast neoplasm"
    ],
    "RIBOCICLIB": [
     "breast cancer",
     "breast neoplasm",
     "breast carcinoma"
    ],
    "TRILACICLIB": [
     "small cell lung carcinoma",
     "myelosuppression"
    ]
   },
   "tractability": [
    {
     "modality": "SM",
     "bucket": "Approved Drug"
    },
    {
     "modality": "SM",
     "bucket": "Structure with Ligand"
    },
    {
     "modality": "SM",
     "bucket": "High-Quality Ligand"
    },
    {
     "modality": "SM",
     "bucket": "High-Quality Pocket"
    },
    {
     "modality": "SM",
     "bucket": "Druggable Family"
    },
    {
     "modality": "PR",
     "bucket": "Literature"
    },
    {
     "modality": "PR",
     "bucket": "Database Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Half-life Data"
    },
    {
     "modality": "PR",
     "bucket": "Small Molecule Binder"
    }
   ]
  }
 ],
 "trials": {
  "by_antigen": {
   "GD2": {
    "n": 24,
    "n_observational": 1,
    "n_active": 10,
    "n_withdrawn": 1,
    "trials": [
     {
      "nct": "NCT03721068",
      "title": "Study of CAR T-Cells Targeting the GD2 With IL-15+iCaspase9 for Relapsed/Refractory Neuroblastoma or Relapsed/Refractory Osteosarcoma",
      "status": "RECRUITING",
      "last_update": "2026-03-27",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05400603",
      "title": "Allogeneic Expanded Gamma Delta T Cells With GD2 Chemoimmunotherapy in Relapsed /Refractory Neuroblastoma or Refractory/ Relapsed Osteosarcoma",
      "status": "RECRUITING",
      "last_update": "2025-12-26",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05968768",
      "title": "To Evaluate the Efficacy and Safety of Naxitamab in Patients With Refractory Ewing's Sarcoma (Butterfly)",
      "status": "RECRUITING",
      "last_update": "2026-08-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06669013",
      "title": "Chemo-immunotherapy in Patients Under 18 Years of Age With Bone and Soft Tissue Sarcomas",
      "status": "RECRUITING",
      "last_update": "2024-11-01",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00003022",
      "title": "Monoclonal Antibody Therapy in Treating Patients With Leptomeningeal Cancer",
      "status": "COMPLETED",
      "last_update": "2013-07-03",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00003023",
      "title": "Monoclonal Antibody A1G4 Plus BCG in Treating Patients With Cancer",
      "status": "COMPLETED",
      "last_update": "2013-01-18",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00003750",
      "title": "Biological Therapy in Treating Children With Refractory or Recurrent Neuroblastoma or Other Tumors",
      "status": "COMPLETED",
      "last_update": "2014-08-08",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00445965",
      "title": "Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer",
      "status": "COMPLETED",
      "last_update": "2024-04-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00743496",
      "title": "A Phase I Trial Of The Humanized Anti-GD2 Antibody In Children And Adolescents With Neuroblastoma, Osteosarcoma, Ewing Sarcoma and Melanoma",
      "status": "COMPLETED",
      "last_update": "2017-08-17",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01953900",
      "title": "iC9-GD2-CAR-VZV-CTLs/Refractory or Metastatic GD2-positive Sarcoma and Neuroblastoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-04-22",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02107963",
      "title": "A Phase I Trial of T Cells Expressing an Anti-GD2 Chimeric Antigen Receptor in Children and Young Adults With GD2+ Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2024-05-16",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02173093",
      "title": "Activated T Cells Armed With GD2 Bispecific Antibody in Children and Young Adults With Neuroblastoma and Osteosarcoma",
      "status": "UNKNOWN",
      "last_update": "2019-01-29",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02484443",
      "title": "Dinutuximab in Combination With Sargramostim in Treating Patients With Recurrent Osteosarcoma",
      "status": "COMPLETED",
      "last_update": "2023-10-26",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02502786",
      "title": "Humanized Monoclonal Antibody 3F8 (Hu3F8) With Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) in the Treatment of Recurrent Osteosarcoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03209869",
      "title": "Treatment of Relapsed or Refractory Neuroblastoma and Osteosarcoma With Expanded Haploidentical NK Cells and Hu14.18-IL2",
      "status": "WITHDRAWN",
      "last_update": "2022-09-13",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03356782",
      "title": "Safety and Efficacy Evaluation of 4th Generation Safety-engineered CAR T Cells Targeting Sarcomas",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-08-26",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03373097",
      "title": "Anti-GD2 CAR T Cells in Pediatric Patients Affected by High Risk and/or Relapsed/Refractory Neuroblastoma or Other GD2-positive Solid Tumors",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-02-05",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03635632",
      "title": "C7R-GD2.CART Cells for Patients With Relapsed or Refractory Neuroblastoma and Other GD2 Positive Cancers (GAIL-N)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-06",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03860207",
      "title": "Study of the Safety and Efficacy of Humanized 3F8 Bispecific Antibody (Hu3F8-BsAb) in Patients With Relapsed/Refractory Neuroblastoma, Osteosarcoma and Other Solid Tumor Cancers",
      "status": "TERMINATED",
      "last_update": "2023-09-13",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04238819",
      "title": "A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Treatments in Children and Young Adult Participants With Solid Tumors, Including Neuroblastoma",
      "status": "COMPLETED",
      "last_update": "2026-03-02",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04433221",
      "title": "Combination Immunotherapy Targeting Sarcomas",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-08-26",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04539366",
      "title": "Testing a New Immune Cell Therapy, GD2-Targeted Modified T-cells (GD2CART), in Children, Adolescents, and Young Adults With Relapsed/Refractory Osteosarcoma and Neuroblastoma, GD2-CAR PERSIST Trial",
      "status": "SUSPENDED",
      "last_update": "2026-08-05",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04751383",
      "title": "Testing the Combination of Two Immunotherapy Drugs (Magrolimab and Dinutuximab) in Patients With Relapsed or Refractory Neuroblastoma or Relapsed Osteosarcoma",
      "status": "TERMINATED",
      "last_update": "2026-06-30",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05558280",
      "title": "Qarziba for Patients in Relapsed/Refractory High-grade Osteosarcoma",
      "status": "SUSPENDED",
      "last_update": "2023-11-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ],
    "cell_therapy": {
     "n": 9,
     "n_observational": 0,
     "n_active": 5,
     "n_withdrawn": 1,
     "trials": [
      {
       "nct": "NCT03721068",
       "title": "Study of CAR T-Cells Targeting the GD2 With IL-15+iCaspase9 for Relapsed/Refractory Neuroblastoma or Relapsed/Refractory Osteosarcoma",
       "status": "RECRUITING",
       "last_update": "2026-03-27",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT05400603",
       "title": "Allogeneic Expanded Gamma Delta T Cells With GD2 Chemoimmunotherapy in Relapsed /Refractory Neuroblastoma or Refractory/ Relapsed Osteosarcoma",
       "status": "RECRUITING",
       "last_update": "2025-12-26",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT02107963",
       "title": "A Phase I Trial of T Cells Expressing an Anti-GD2 Chimeric Antigen Receptor in Children and Young Adults With GD2+ Solid Tumors",
       "status": "COMPLETED",
       "last_update": "2024-05-16",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT02173093",
       "title": "Activated T Cells Armed With GD2 Bispecific Antibody in Children and Young Adults With Neuroblastoma and Osteosarcoma",
       "status": "UNKNOWN",
       "last_update": "2019-01-29",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT03209869",
       "title": "Treatment of Relapsed or Refractory Neuroblastoma and Osteosarcoma With Expanded Haploidentical NK Cells and Hu14.18-IL2",
       "status": "WITHDRAWN",
       "last_update": "2022-09-13",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT03356782",
       "title": "Safety and Efficacy Evaluation of 4th Generation Safety-engineered CAR T Cells Targeting Sarcomas",
       "status": "NOT_YET_RECRUITING",
       "last_update": "2026-08-26",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT03373097",
       "title": "Anti-GD2 CAR T Cells in Pediatric Patients Affected by High Risk and/or Relapsed/Refractory Neuroblastoma or Other GD2-positive Solid Tumors",
       "status": "ACTIVE_NOT_RECRUITING",
       "last_update": "2025-02-05",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT03635632",
       "title": "C7R-GD2.CART Cells for Patients With Relapsed or Refractory Neuroblastoma and Other GD2 Positive Cancers (GAIL-N)",
       "status": "ACTIVE_NOT_RECRUITING",
       "last_update": "2026-07-06",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT04539366",
       "title": "Testing a New Immune Cell Therapy, GD2-Targeted Modified T-cells (GD2CART), in Children, Adolescents, and Young Adults With Relapsed/Refractory Osteosarcoma and Neuroblastoma, GD2-CAR PERSIST Trial",
       "status": "SUSPENDED",
       "last_update": "2026-08-05",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      }
     ]
    },
    "synonyms_searched": [
     "GD2",
     "dinutuximab",
     "naxitamab"
    ]
   },
   "B7-H3": {
    "n": 12,
    "n_observational": 3,
    "n_active": 9,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT04897321",
      "title": "B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)",
      "status": "RECRUITING",
      "last_update": "2026-05-19",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06500819",
      "title": "Autologous B7-H3 Chimeric Antigen Receptor T Cells in Relapsed/Refractory Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2026-05-07",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06778603",
      "title": "B7-H3 NIR Imaging for Osteosarcoma Surgery",
      "status": "RECRUITING",
      "last_update": "2025-01-16",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07172958",
      "title": "Selective Antigen Specific T Cells and CAR T Cells in Subjects With Relapsed/Refractory Embryonal Tumors (SABRE)",
      "status": "RECRUITING",
      "last_update": "2026-08-13",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07222735",
      "title": "Hypofractionated Radiation in Combination With B7-H3-CAR T Cells for Pediatric Patients With Relapsed/Refractory Sarcomas",
      "status": "RECRUITING",
      "last_update": "2026-02-09",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07428993",
      "title": "Evaluating Efficacy of B7-H3-CAR T Cells Administered at the End of Upfront Map Chemotherapy in Patients With Newly Diagnosed High-Risk Osteosarcoma",
      "status": "RECRUITING",
      "last_update": "2026-09-01",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07774533",
      "title": "68Ga-B7-H3 Nanobody ImmunoPET in Osteosarcoma",
      "status": "RECRUITING",
      "last_update": "2026-08-19",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00089245",
      "title": "Radiolabeled MAB Therapy in Patients With Refractory, Recurrent, or Advanced CNS or Leptomeningeal Cancer",
      "status": "TERMINATED",
      "last_update": "2023-12-26",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02982941",
      "title": "Enoblituzumab (MGA271) in Children With B7-H3-expressing Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2022-02-08",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04433221",
      "title": "Combination Immunotherapy Targeting Sarcomas",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-08-26",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04864821",
      "title": "Clinical Study of CD276 Targeted Autologous Chimeric Antigen Receptor T Cell Infusion in Patients With CD276 Positive Advanced Solid Tumor",
      "status": "UNKNOWN",
      "last_update": "2021-05-06",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06699576",
      "title": "ARTEMIS-103: Phase 1b Study of HS-20093 Combinations in Patients with Bone and Soft Tissue Sarcoma.",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2024-11-21",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     }
    ],
    "cell_therapy": {
     "n": 6,
     "n_observational": 0,
     "n_active": 5,
     "n_withdrawn": 0,
     "trials": [
      {
       "nct": "NCT04897321",
       "title": "B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)",
       "status": "RECRUITING",
       "last_update": "2026-05-19",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT06500819",
       "title": "Autologous B7-H3 Chimeric Antigen Receptor T Cells in Relapsed/Refractory Solid Tumors",
       "status": "RECRUITING",
       "last_update": "2026-05-07",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT07172958",
       "title": "Selective Antigen Specific T Cells and CAR T Cells in Subjects With Relapsed/Refractory Embryonal Tumors (SABRE)",
       "status": "RECRUITING",
       "last_update": "2026-08-13",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT07222735",
       "title": "Hypofractionated Radiation in Combination With B7-H3-CAR T Cells for Pediatric Patients With Relapsed/Refractory Sarcomas",
       "status": "RECRUITING",
       "last_update": "2026-02-09",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT07428993",
       "title": "Evaluating Efficacy of B7-H3-CAR T Cells Administered at the End of Upfront Map Chemotherapy in Patients With Newly Diagnosed High-Risk Osteosarcoma",
       "status": "RECRUITING",
       "last_update": "2026-09-01",
       "phase": "PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT04864821",
       "title": "Clinical Study of CD276 Targeted Autologous Chimeric Antigen Receptor T Cell Infusion in Patients With CD276 Positive Advanced Solid Tumor",
       "status": "UNKNOWN",
       "last_update": "2021-05-06",
       "phase": "EARLY_PHASE1",
       "study_type": "INTERVENTIONAL"
      }
     ]
    },
    "synonyms_searched": [
     "B7-H3",
     "CD276",
     "omburtamab",
     "enoblituzumab"
    ]
   },
   "HER2": {
    "n": 7,
    "n_observational": 1,
    "n_active": 4,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT04616560",
      "title": "Trastuzumab Deruxtecan (DS-8201a) for the Treatment of Recurrent or Refractory Osteosarcoma, Wilms Tumor, and Desmoplastic Small Round Cell Tumor",
      "status": "RECRUITING",
      "last_update": "2026-09-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04995003",
      "title": "HER2 Chimeric Antigen Receptor (CAR) T Cells in Combination With Checkpoint Blockade in Patients With Advanced Sarcoma",
      "status": "RECRUITING",
      "last_update": "2026-01-22",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07066982",
      "title": "Sequential Infusion of CD146-Targeted and HER2-Targeted CAR T Cells in Patients With Advanced Sarcomas",
      "status": "RECRUITING",
      "last_update": "2025-07-15",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00005033",
      "title": "Trastuzumab in Treating Patients With Recurrent Osteosarcoma",
      "status": "COMPLETED",
      "last_update": "2013-06-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00023998",
      "title": "Chemotherapy With or Without Trastuzumab in Treating Patients With Metastatic Osteosarcoma",
      "status": "COMPLETED",
      "last_update": "2013-02-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01320592",
      "title": "PD0332991/Paclitaxel in Advanced Breast Cancer",
      "status": "COMPLETED",
      "last_update": "2020-04-08",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04433221",
      "title": "Combination Immunotherapy Targeting Sarcomas",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-08-26",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ],
    "cell_therapy": {
     "n": 2,
     "n_observational": 0,
     "n_active": 2,
     "n_withdrawn": 0,
     "trials": [
      {
       "nct": "NCT04995003",
       "title": "HER2 Chimeric Antigen Receptor (CAR) T Cells in Combination With Checkpoint Blockade in Patients With Advanced Sarcoma",
       "status": "RECRUITING",
       "last_update": "2026-01-22",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT07066982",
       "title": "Sequential Infusion of CD146-Targeted and HER2-Targeted CAR T Cells in Patients With Advanced Sarcomas",
       "status": "RECRUITING",
       "last_update": "2025-07-15",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      }
     ]
    },
    "synonyms_searched": [
     "HER2",
     "ERBB2",
     "trastuzumab",
     "trastuzumab deruxtecan"
    ]
   },
   "VEGFR": {
    "n": 47,
    "n_observational": 0,
    "n_active": 17,
    "n_withdrawn": 1,
    "trials": [
     {
      "nct": "NCT04055220",
      "title": "Efficacy and Safety of Regorafenib as Maintenance Therapy After First-line Treatment in Patients With Bone Sarcomas",
      "status": "RECRUITING",
      "last_update": "2026-02-17",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04698785",
      "title": "Efficacy of Regorafenib Combined With Best Supportive Care as Maintenance Treatment in High Grade Bone Sarcomas Patients",
      "status": "RECRUITING",
      "last_update": "2026-02-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05019703",
      "title": "Atezolizumab and Cabozantinib for the Treatment of Adolescents and Young Adults With Recurrent or Metastatic Osteosarcoma, TACOS Study",
      "status": "RECRUITING",
      "last_update": "2026-04-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05135975",
      "title": "A Study of Cabozantinib as a Maintenance Agent to Prevent Progression or Recurrence in High-Risk Pediatric Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2025-08-12",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05182164",
      "title": "Combination of Pembrolizumab and Cabozantinib in Patients With Advanced Sarcomas",
      "status": "RECRUITING",
      "last_update": "2025-10-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06156410",
      "title": "Cabozantinib With Ifosfamide in Relapsed/Refractory Sarcomas",
      "status": "RECRUITING",
      "last_update": "2026-09-03",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06239272",
      "title": "NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)",
      "status": "RECRUITING",
      "last_update": "2026-08-03",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07194044",
      "title": "Metastatic Ewing's Trial Testing Schedule Enhancement to Improve Outcomes",
      "status": "RECRUITING",
      "last_update": "2026-08-28",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07479732",
      "title": "Apatinib Combined With Liposomal Irinotecan for Refractory or Metastatic Osteosarcoma",
      "status": "RECRUITING",
      "last_update": "2026-03-18",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07787429",
      "title": "Evaluation of the Safety and Efficacy of Mifamurtide Versus Standard Treatment With Sorafenib in Patients With High-risk Osteosarcoma",
      "status": "RECRUITING",
      "last_update": "2026-08-26",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00330421",
      "title": "Sorafenib in Treating Patients With Soft Tissue Sarcomas (Extremity Sarcoma Closed to Entry as of 5/30/07)",
      "status": "COMPLETED",
      "last_update": "2014-04-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00880542",
      "title": "Sorafenib and Ifosfamide in Treating Patients With High-Grade Soft Tissue Sarcoma or Bone Sarcoma That Can Be Removed by Surgery",
      "status": "TERMINATED",
      "last_update": "2020-08-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00889057",
      "title": "Sorafenib in Relapsed High Grade Osteosarcoma",
      "status": "COMPLETED",
      "last_update": "2013-03-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01130623",
      "title": "A Phase I Study of Pazopanib as a Single Agent for Children With Refractory Solid Tumors",
      "status": "WITHDRAWN",
      "last_update": "2017-07-02",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01518413",
      "title": "Dose Escalation Study of Sorafenib and Irinotecan Combination Therapy in Pediatric Patients With Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2015-02-27",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01532687",
      "title": "Gemcitabine With or Without Pazopanib in Treating Patients With Refractory Soft Tissue Sarcoma",
      "status": "COMPLETED",
      "last_update": "2021-09-27",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01759303",
      "title": "Study of Pazopanib in the Treatment of Osteosarcoma Metastatic to the Lung",
      "status": "TERMINATED",
      "last_update": "2021-04-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01804374",
      "title": "Phase II Open Label, Non-randomized Study of Sorafenib and Everolimus in Relapsed and Non-resectable Osteosarcoma",
      "status": "COMPLETED",
      "last_update": "2015-06-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02048371",
      "title": "SARC024: A Blanket Protocol to Study Oral Regorafenib in Patients With Selected Sarcoma Subtypes",
      "status": "COMPLETED",
      "last_update": "2023-11-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02085148",
      "title": "A Phase I Dose Finding Study in Children With Solid Tumors Recurrent or Refractory to Standard Therapy",
      "status": "COMPLETED",
      "last_update": "2024-04-22",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02180867",
      "title": "Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery",
      "status": "COMPLETED",
      "last_update": "2026-06-17",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02243605",
      "title": "Cabozantinib S-malate in Treating Patients With Relapsed Osteosarcoma or Ewing Sarcoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02357810",
      "title": "Pazopanib Hydrochloride and Topotecan Hydrochloride in Treating Patients With Metastatic Soft Tissue and Bone Sarcomas",
      "status": "COMPLETED",
      "last_update": "2022-06-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02389244",
      "title": "A Phase II Study Evaluating Efficacy and Safety of Regorafenib in Patients With Metastatic Bone Sarcomas",
      "status": "COMPLETED",
      "last_update": "2026-07-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02432274",
      "title": "Study of Lenvatinib in Children and Adolescents With Refractory or Relapsed Solid Malignancies and Young Adults With Osteosarcoma",
      "status": "COMPLETED",
      "last_update": "2023-07-11",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02711007",
      "title": "Apatinib for Advanced Osteosarcoma After Failure of Standard Multimodal Therapy",
      "status": "COMPLETED",
      "last_update": "2018-04-23",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02867592",
      "title": "Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03163381",
      "title": "Apatinib Second Line Treatment for Advanced Osteosarcoma and Soft Tissue Sarcomas ,Openting ,Single Center, One-armed Clinical Study.",
      "status": "UNKNOWN",
      "last_update": "2017-05-23",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03359018",
      "title": "Apatinib Plus Anti-PD1 Therapy for Advanced Osteosarcoma",
      "status": "COMPLETED",
      "last_update": "2020-05-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03491371",
      "title": "Apatinib for Advanced Sarcoma: Results From Multiple Institutions' Off-label Use",
      "status": "COMPLETED",
      "last_update": "2018-04-10",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03539172",
      "title": "Radiotherapy Concurrent With Apatinib in Advanced Soft Tissue and Bone Sarcomas of Head and Neck--RASS Study",
      "status": "UNKNOWN",
      "last_update": "2018-05-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03742193",
      "title": "Pulmonary Resectable Metastases of Osteosarcoma With Anti-angiogenics and CHemotherapy",
      "status": "UNKNOWN",
      "last_update": "2023-11-01",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04154189",
      "title": "A Study to Compare the Efficacy and Safety of Ifosfamide and Etoposide With or Without Lenvatinib in Children, Adolescents and Young Adults With Relapsed and Refractory Osteosarcoma",
      "status": "COMPLETED",
      "last_update": "2024-07-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04351308",
      "title": "Comparison of MAPI+Camrelizumab Versus API+Apatinib Versus MAPI in Patients With a Poor Response to Preoperative Chemotherapy for Newly Diagnosed High-grade Osteosarcoma",
      "status": "UNKNOWN",
      "last_update": "2020-05-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04661852",
      "title": "Cabozantinib With Topotecan-Cyclophosphamide",
      "status": "COMPLETED",
      "last_update": "2023-02-15",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04690231",
      "title": "Apatinib + Ifosfamide and Etoposide for Relapsed or Refractory Osteosarcoma",
      "status": "COMPLETED",
      "last_update": "2022-03-15",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04803877",
      "title": "SARC038: Phase 2 Study of Regorafenib and Nivolumab in Osteosarcoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-10-31",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04824352",
      "title": "Apatinib Plus IE Chemotherapy (Ifosfamide and Etoposide) for Relapsed or Refractory Osteosarcoma",
      "status": "SUSPENDED",
      "last_update": "2024-05-14",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05277480",
      "title": "Apatinib With Ifosfamide Plus Etoposide for Relapsed or Refractory Osteosarcoma (OAIE)",
      "status": "COMPLETED",
      "last_update": "2024-07-31",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05395741",
      "title": "Regorafenib in Patients With Refractory Primary Bone Tumors",
      "status": "COMPLETED",
      "last_update": "2026-08-21",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05691478",
      "title": "A Study to Test the Addition of the Drug Cabozantinib to Chemotherapy in Patients With Newly Diagnosed Osteosarcoma",
      "status": "SUSPENDED",
      "last_update": "2026-09-08",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05830084",
      "title": "Phase Ib / Regorafenib With Conventional Chemotherapy/Newly Diagnosed Patients/ Multimetastatic Ewing Sarcoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-01-06",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06041490",
      "title": "Adjuvant Therapy for High-risk Hepatocellular Carcinoma Post Liver Transplantation",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2023-09-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06125171",
      "title": "Tucidinostat Plus Apatinib for Advanced Osteosarcoma",
      "status": "UNKNOWN",
      "last_update": "2023-11-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06341712",
      "title": "Effects of Maintenance Cabozantinib+BSC Versus BSC in Children and AYA With Osteosarcoma",
      "status": "TERMINATED",
      "last_update": "2026-03-31",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06820957",
      "title": "Testing a New Combination of Anti-cancer Drugs in Patients Newly Diagnosed With Ewing Sarcoma Who Have Cancer That Has Spread to Other Parts of the Body",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-21",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07619950",
      "title": "EVERolimus and LenvAtinib Versus Everolimus for Bone Sarcoma",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-06-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ],
    "cell_therapy": {
     "n": 0,
     "n_observational": 0,
     "n_active": 0,
     "n_withdrawn": 0,
     "trials": []
    },
    "synonyms_searched": [
     "VEGFR",
     "regorafenib",
     "cabozantinib",
     "sorafenib",
     "apatinib",
     "lenvatinib",
     "pazopanib"
    ]
   },
   "PD-1": {
    "n": 32,
    "n_observational": 4,
    "n_active": 16,
    "n_withdrawn": 1,
    "trials": [
     {
      "nct": "NCT04282044",
      "title": "Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies",
      "status": "RECRUITING",
      "last_update": "2024-02-08",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04995003",
      "title": "HER2 Chimeric Antigen Receptor (CAR) T Cells in Combination With Checkpoint Blockade in Patients With Advanced Sarcoma",
      "status": "RECRUITING",
      "last_update": "2026-01-22",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05182164",
      "title": "Combination of Pembrolizumab and Cabozantinib in Patients With Advanced Sarcomas",
      "status": "RECRUITING",
      "last_update": "2025-10-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05492682",
      "title": "START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer",
      "status": "RECRUITING",
      "last_update": "2026-05-12",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06074692",
      "title": "PARP Inhibition, Stereotactic Body Radiotherapy and Immunotherapy for Metastatic or Advanced Sarcoma (PRIMA)",
      "status": "RECRUITING",
      "last_update": "2023-10-31",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06114225",
      "title": "Pulmonary Resectable Osteosarcoma Treated by Metastasectomy and Pre-operative Immunotherapy and Stereotactic Body Radiotherapy (PROMIS): a Prospective Clinical Trial",
      "status": "RECRUITING",
      "last_update": "2023-11-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06638931",
      "title": "Agnostic Therapy in Rare Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2026-04-15",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07602049",
      "title": "Cryoablation Plus Camrelizumab for Advanced Soft Tissue Sarcoma",
      "status": "RECRUITING",
      "last_update": "2026-05-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07648069",
      "title": "Tumor Neoantigen Vaccine SarVac Combined With Tumor Specific Lymphocyte Reinfusion in the Treatment of Advanced Sarcoma",
      "status": "RECRUITING",
      "last_update": "2026-06-15",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02301039",
      "title": "SARC028: A Phase II Study of the Anti-PD1 Antibody Pembrolizumab (MK-3475) in Patients With Advanced Sarcomas",
      "status": "COMPLETED",
      "last_update": "2020-09-29",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02304458",
      "title": "Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas",
      "status": "COMPLETED",
      "last_update": "2023-10-17",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02406781",
      "title": "Combination of MK3475 and Metronomic Cyclophosphamide in Patients With Advanced Sarcomas : Multicentre Phase II Trial",
      "status": "COMPLETED",
      "last_update": "2025-12-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02500797",
      "title": "Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Sarcoma That Cannot Be Removed by Surgery",
      "status": "COMPLETED",
      "last_update": "2023-10-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02982486",
      "title": "A Phase II of Nivolumab Plus Ipilimumab in Non-resectable Sarcoma and Endometrial Carcinoma",
      "status": "UNKNOWN",
      "last_update": "2017-11-01",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03013127",
      "title": "A Study of Pembrolizumab in Patients With Relapsed Or Metastatic Osteosarcoma Not Eligible for Curative Surgery",
      "status": "TERMINATED",
      "last_update": "2020-10-14",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03190174",
      "title": "Nivolumab (Opdivo\u00ae) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma and Certain Cancers",
      "status": "COMPLETED",
      "last_update": "2025-02-17",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03277924",
      "title": "Trial of Sunitinib and/or Nivolumab Plus Chemotherapy in Advanced Soft Tissue and Bone Sarcomas",
      "status": "COMPLETED",
      "last_update": "2024-08-13",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03356782",
      "title": "Safety and Efficacy Evaluation of 4th Generation Safety-engineered CAR T Cells Targeting Sarcomas",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-08-26",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03359018",
      "title": "Apatinib Plus Anti-PD1 Therapy for Advanced Osteosarcoma",
      "status": "COMPLETED",
      "last_update": "2020-05-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03449108",
      "title": "LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-05-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03628209",
      "title": "Nivolumab or Nivolumab and Azacitidine in Patients With Recurrent, Resectable Osteosarcoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-30",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04044378",
      "title": "Famitinib Plus Camrelizumab & Famitinib Alone & Famitinib Plus Ifosfamide in Advanced Osteosarcoma",
      "status": "WITHDRAWN",
      "last_update": "2020-05-19",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04294511",
      "title": "Study of Camrelizumab in Combination With Neoadjuvant Chemotherapy in the Treatment of Osteosarcoma",
      "status": "UNKNOWN",
      "last_update": "2020-03-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04351308",
      "title": "Comparison of MAPI+Camrelizumab Versus API+Apatinib Versus MAPI in Patients With a Poor Response to Preoperative Chemotherapy for Newly Diagnosed High-grade Osteosarcoma",
      "status": "UNKNOWN",
      "last_update": "2020-05-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04483778",
      "title": "B7H3 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-04-28",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04616248",
      "title": "In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable and Metastatic Solid Tumors",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-06-18",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04730349",
      "title": "A Study of Bempegaldesleukin (BEMPEG: NKTR-214) in Combination With Nivolumab in Children, Adolescents and Young Adults With Recurrent or Treatment-resistant Cancer",
      "status": "TERMINATED",
      "last_update": "2023-03-24",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04803877",
      "title": "SARC038: Phase 2 Study of Regorafenib and Nivolumab in Osteosarcoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-10-31",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05302921",
      "title": "Neoadjuvant Dual Checkpoint Inhibition and Cryoablation in Relapsed/Refractory Pediatric Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2025-01-01",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05851456",
      "title": "A Clinical Study on Oncolytic Virus Injection (R130) for the Treatment of Relapsed/Refractory Bone and Soft Tissue Tumors",
      "status": "UNKNOWN",
      "last_update": "2023-05-09",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06171282",
      "title": "A Clinical Study on Oncolytic Virus Injection (R130) for the Treatment of Advanced Bone and Soft Tissue Tumors",
      "status": "UNKNOWN",
      "last_update": "2023-12-14",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07695311",
      "title": "EWSR1 Immunotherapy in Ewing Sarcoma and DSRCT",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-08-31",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     }
    ],
    "cell_therapy": {
     "n": 5,
     "n_observational": 0,
     "n_active": 4,
     "n_withdrawn": 0,
     "trials": [
      {
       "nct": "NCT04995003",
       "title": "HER2 Chimeric Antigen Receptor (CAR) T Cells in Combination With Checkpoint Blockade in Patients With Advanced Sarcoma",
       "status": "RECRUITING",
       "last_update": "2026-01-22",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT07648069",
       "title": "Tumor Neoantigen Vaccine SarVac Combined With Tumor Specific Lymphocyte Reinfusion in the Treatment of Advanced Sarcoma",
       "status": "RECRUITING",
       "last_update": "2026-06-15",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT03356782",
       "title": "Safety and Efficacy Evaluation of 4th Generation Safety-engineered CAR T Cells Targeting Sarcomas",
       "status": "NOT_YET_RECRUITING",
       "last_update": "2026-08-26",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT04483778",
       "title": "B7H3 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults",
       "status": "ACTIVE_NOT_RECRUITING",
       "last_update": "2026-04-28",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT04730349",
       "title": "A Study of Bempegaldesleukin (BEMPEG: NKTR-214) in Combination With Nivolumab in Children, Adolescents and Young Adults With Recurrent or Treatment-resistant Cancer",
       "status": "TERMINATED",
       "last_update": "2023-03-24",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      }
     ]
    },
    "synonyms_searched": [
     "PD-1",
     "pembrolizumab",
     "nivolumab",
     "camrelizumab"
    ]
   },
   "IGF-1R": {
    "n": 10,
    "n_observational": 1,
    "n_active": 1,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT00563680",
      "title": "QUILT-3.025: A Phase 2 Study of AMG 479 in Relapsed or Refractory Ewing's Family Tumor and Desmoplastic Small Round Cell Tumors",
      "status": "COMPLETED",
      "last_update": "2016-10-27",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00617890",
      "title": "A Study to Determine the Activity of Robatumumab (SCH 717454) in Participants With Relapsed Osteosarcoma or Ewing's Sarcoma (MK-7454-002/P04720)",
      "status": "TERMINATED",
      "last_update": "2018-08-23",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00668148",
      "title": "A Five-Tier, Open-Label Study of IMC-A12 in Advanced Sarcoma",
      "status": "COMPLETED",
      "last_update": "2018-07-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00720174",
      "title": "Cixutumumab and Doxorubicin Hydrochloride in Treating Patients With Unresectable, Locally Advanced, or Metastatic Soft Tissue Sarcoma",
      "status": "COMPLETED",
      "last_update": "2016-05-17",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00831844",
      "title": "Cixutumumab in Treating Patients With Relapsed or Refractory Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2015-03-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01016015",
      "title": "Temsirolimus and Cixutumumab in Treating Patients With Locally Advanced, Metastatic, or Recurrent Soft Tissue Sarcoma or Bone Sarcoma",
      "status": "COMPLETED",
      "last_update": "2015-07-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01614795",
      "title": "Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma",
      "status": "COMPLETED",
      "last_update": "2018-12-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02306161",
      "title": "Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-29",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02546544",
      "title": "Eurosarc Trial of Linsitinib in Advanced Ewing Sarcoma",
      "status": "COMPLETED",
      "last_update": "2019-06-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04129151",
      "title": "Palbociclib + Ganitumab In Ewing Sarcoma",
      "status": "TERMINATED",
      "last_update": "2024-08-01",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ],
    "cell_therapy": {
     "n": 0,
     "n_observational": 0,
     "n_active": 0,
     "n_withdrawn": 0,
     "trials": []
    },
    "synonyms_searched": [
     "IGF-1R",
     "IGF1R",
     "ganitumab",
     "cixutumumab"
    ]
   },
   "CDK4/6": {
    "n": 12,
    "n_observational": 0,
    "n_active": 5,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT04040205",
      "title": "Abemaciclib for Bone and Soft Tissue Sarcoma With Cyclin-Dependent Kinase (CDK) Pathway Alteration",
      "status": "RECRUITING",
      "last_update": "2026-07-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06699472",
      "title": "A Prospective, Randomized, Controlled Clinical Study on the Prevention of Chemotherapy Related Myelosuppression in Patients with Ewing's Sarcoma Using Trilaciclib",
      "status": "RECRUITING",
      "last_update": "2024-11-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01291017",
      "title": "Cyclin Dependent Kinase (CDK)4/6 Inhibitor, PD0332991 in Advanced Non-small Cell Lung Cancer NSCLC.",
      "status": "COMPLETED",
      "last_update": "2016-05-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01320592",
      "title": "PD0332991/Paclitaxel in Advanced Breast Cancer",
      "status": "COMPLETED",
      "last_update": "2020-04-08",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02644460",
      "title": "Abemaciclib in Children With DIPG or Recurrent/Refractory Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2023-10-26",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03155620",
      "title": "Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03242382",
      "title": "Trial of Palbociclib in Second Line of Advanced Sarcomas With CDK4 Overexpression.",
      "status": "UNKNOWN",
      "last_update": "2024-01-23",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03526250",
      "title": "Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial)",
      "status": "COMPLETED",
      "last_update": "2026-04-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03709680",
      "title": "Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-01-14",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04129151",
      "title": "Palbociclib + Ganitumab In Ewing Sarcoma",
      "status": "TERMINATED",
      "last_update": "2024-08-01",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04238819",
      "title": "A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Treatments in Children and Young Adult Participants With Solid Tumors, Including Neuroblastoma",
      "status": "COMPLETED",
      "last_update": "2026-03-02",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05440786",
      "title": "CAMPFIRE: A Study of Abemaciclib (LY2835219) in Participants With Ewing's Sarcoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-04-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ],
    "cell_therapy": {
     "n": 0,
     "n_observational": 0,
     "n_active": 0,
     "n_withdrawn": 0,
     "trials": []
    },
    "synonyms_searched": [
     "CDK4",
     "palbociclib",
     "abemaciclib"
    ]
   },
   "MDM2": {
    "n": 0,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [],
    "cell_therapy": {
     "n": 0,
     "n_observational": 0,
     "n_active": 0,
     "n_withdrawn": 0,
     "trials": []
    },
    "synonyms_searched": [
     "MDM2",
     "milademetan",
     "navtemadlin"
    ]
   }
  },
  "by_drug": {
   "8H9 131I": {
    "n": 1,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT00089245",
      "title": "Radiolabeled MAB Therapy in Patients With Refractory, Recurrent, or Advanced CNS or Leptomeningeal Cancer",
      "status": "TERMINATED",
      "last_update": "2023-12-26",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "ABEMACICLIB": {
    "n": 4,
    "n_observational": 0,
    "n_active": 2,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT04040205",
      "title": "Abemaciclib for Bone and Soft Tissue Sarcoma With Cyclin-Dependent Kinase (CDK) Pathway Alteration",
      "status": "RECRUITING",
      "last_update": "2026-07-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02644460",
      "title": "Abemaciclib in Children With DIPG or Recurrent/Refractory Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2023-10-26",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04238819",
      "title": "A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Treatments in Children and Young Adult Participants With Solid Tumors, Including Neuroblastoma",
      "status": "COMPLETED",
      "last_update": "2026-03-02",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05440786",
      "title": "CAMPFIRE: A Study of Abemaciclib (LY2835219) in Participants With Ewing's Sarcoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-04-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "ALVOCIDIB": {
    "n": 1,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT00012181",
      "title": "Flavopiridol in Treating Children With Relapsed or Refractory Solid Tumors or Lymphomas",
      "status": "COMPLETED",
      "last_update": "2013-07-02",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "BEVACIZUMAB": {
    "n": 5,
    "n_observational": 0,
    "n_active": 2,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT03715933",
      "title": "Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas",
      "status": "RECRUITING",
      "last_update": "2026-09-08",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00667342",
      "title": "A Study of Bevacizumab in Combination With Chemotherapy for Treatment of Osteosarcoma",
      "status": "COMPLETED",
      "last_update": "2023-08-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01492673",
      "title": "Cyclophosphamide, Topotecan, and Bevacizumab (CTB) in Patients With Relapsed/Refractory Ewing's Sarcoma and Neuroblastoma",
      "status": "COMPLETED",
      "last_update": "2019-10-29",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04861948",
      "title": "IBI188 Combination Therapy in Solid Tumors",
      "status": "TERMINATED",
      "last_update": "2022-10-04",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06041490",
      "title": "Adjuvant Therapy for High-risk Hepatocellular Carcinoma Post Liver Transplantation",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2023-09-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "CABOZANTINIB": {
    "n": 10,
    "n_observational": 0,
    "n_active": 7,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT05019703",
      "title": "Atezolizumab and Cabozantinib for the Treatment of Adolescents and Young Adults With Recurrent or Metastatic Osteosarcoma, TACOS Study",
      "status": "RECRUITING",
      "last_update": "2026-04-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05135975",
      "title": "A Study of Cabozantinib as a Maintenance Agent to Prevent Progression or Recurrence in High-Risk Pediatric Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2025-08-12",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05182164",
      "title": "Combination of Pembrolizumab and Cabozantinib in Patients With Advanced Sarcomas",
      "status": "RECRUITING",
      "last_update": "2025-10-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06156410",
      "title": "Cabozantinib With Ifosfamide in Relapsed/Refractory Sarcomas",
      "status": "RECRUITING",
      "last_update": "2026-09-03",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07194044",
      "title": "Metastatic Ewing's Trial Testing Schedule Enhancement to Improve Outcomes",
      "status": "RECRUITING",
      "last_update": "2026-08-28",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02243605",
      "title": "Cabozantinib S-malate in Treating Patients With Relapsed Osteosarcoma or Ewing Sarcoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02867592",
      "title": "Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04661852",
      "title": "Cabozantinib With Topotecan-Cyclophosphamide",
      "status": "COMPLETED",
      "last_update": "2023-02-15",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05691478",
      "title": "A Study to Test the Addition of the Drug Cabozantinib to Chemotherapy in Patients With Newly Diagnosed Osteosarcoma",
      "status": "SUSPENDED",
      "last_update": "2026-09-08",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06341712",
      "title": "Effects of Maintenance Cabozantinib+BSC Versus BSC in Children and AYA With Osteosarcoma",
      "status": "TERMINATED",
      "last_update": "2026-03-31",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "CABOZANTINIB S-MALATE": {
    "n": 3,
    "n_observational": 0,
    "n_active": 2,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT02243605",
      "title": "Cabozantinib S-malate in Treating Patients With Relapsed Osteosarcoma or Ewing Sarcoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02867592",
      "title": "Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05691478",
      "title": "A Study to Test the Addition of the Drug Cabozantinib to Chemotherapy in Patients With Newly Diagnosed Osteosarcoma",
      "status": "SUSPENDED",
      "last_update": "2026-09-08",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "CATEQUENTINIB": {
    "n": 4,
    "n_observational": 0,
    "n_active": 2,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT03416517",
      "title": "Anlotinib and Irinotecan for Ewing Sarcoma",
      "status": "UNKNOWN",
      "last_update": "2019-02-15",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06438783",
      "title": "TQB2928 Injection Combined Anlotinib Hydrochloride Capsule in Recurrent/Metastatic Osteosarcoma and Other Solid Tumors",
      "status": "TERMINATED",
      "last_update": "2025-12-12",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06699576",
      "title": "ARTEMIS-103: Phase 1b Study of HS-20093 Combinations in Patients with Bone and Soft Tissue Sarcoma.",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2024-11-21",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07444918",
      "title": "Liposomal Irinotecan, Vincristine, Temozolomide, and Anlotinib for R/R Pediatric Solid Tumors",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-03-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "CIXUTUMUMAB": {
    "n": 5,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT00668148",
      "title": "A Five-Tier, Open-Label Study of IMC-A12 in Advanced Sarcoma",
      "status": "COMPLETED",
      "last_update": "2018-07-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00720174",
      "title": "Cixutumumab and Doxorubicin Hydrochloride in Treating Patients With Unresectable, Locally Advanced, or Metastatic Soft Tissue Sarcoma",
      "status": "COMPLETED",
      "last_update": "2016-05-17",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00831844",
      "title": "Cixutumumab in Treating Patients With Relapsed or Refractory Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2015-03-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01016015",
      "title": "Temsirolimus and Cixutumumab in Treating Patients With Locally Advanced, Metastatic, or Recurrent Soft Tissue Sarcoma or Bone Sarcoma",
      "status": "COMPLETED",
      "last_update": "2015-07-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01614795",
      "title": "Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma",
      "status": "COMPLETED",
      "last_update": "2018-12-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "ENOBLITUZUMAB": {
    "n": 1,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT02982941",
      "title": "Enoblituzumab (MGA271) in Children With B7-H3-expressing Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2022-02-08",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "FAMITINIB": {
    "n": 1,
    "n_observational": 2,
    "n_active": 0,
    "n_withdrawn": 1,
    "trials": [
     {
      "nct": "NCT04044378",
      "title": "Famitinib Plus Camrelizumab & Famitinib Alone & Famitinib Plus Ifosfamide in Advanced Osteosarcoma",
      "status": "WITHDRAWN",
      "last_update": "2020-05-19",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "FIGITUMUMAB": {
    "n": 1,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT00474760",
      "title": "Study Of Anti-IGF-IR CP-751,871 In Patients With Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2013-12-17",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "FRUQUINTINIB": {
    "n": 0,
    "n_observational": 1,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": []
   },
   "GANITUMAB": {
    "n": 3,
    "n_observational": 1,
    "n_active": 1,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT00563680",
      "title": "QUILT-3.025: A Phase 2 Study of AMG 479 in Relapsed or Refractory Ewing's Family Tumor and Desmoplastic Small Round Cell Tumors",
      "status": "COMPLETED",
      "last_update": "2016-10-27",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02306161",
      "title": "Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-29",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04129151",
      "title": "Palbociclib + Ganitumab In Ewing Sarcoma",
      "status": "TERMINATED",
      "last_update": "2024-08-01",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "LENVATINIB": {
    "n": 4,
    "n_observational": 0,
    "n_active": 2,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT02432274",
      "title": "Study of Lenvatinib in Children and Adolescents With Refractory or Relapsed Solid Malignancies and Young Adults With Osteosarcoma",
      "status": "COMPLETED",
      "last_update": "2023-07-11",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04154189",
      "title": "A Study to Compare the Efficacy and Safety of Ifosfamide and Etoposide With or Without Lenvatinib in Children, Adolescents and Young Adults With Relapsed and Refractory Osteosarcoma",
      "status": "COMPLETED",
      "last_update": "2024-07-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06041490",
      "title": "Adjuvant Therapy for High-risk Hepatocellular Carcinoma Post Liver Transplantation",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2023-09-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07619950",
      "title": "EVERolimus and LenvAtinib Versus Everolimus for Bone Sarcoma",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-06-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "LINSITINIB": {
    "n": 1,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT02546544",
      "title": "Eurosarc Trial of Linsitinib in Advanced Ewing Sarcoma",
      "status": "COMPLETED",
      "last_update": "2019-06-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "MECASERMIN RINFABATE": {
    "n": 2,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT00563680",
      "title": "QUILT-3.025: A Phase 2 Study of AMG 479 in Relapsed or Refractory Ewing's Family Tumor and Desmoplastic Small Round Cell Tumors",
      "status": "COMPLETED",
      "last_update": "2016-10-27",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01016015",
      "title": "Temsirolimus and Cixutumumab in Treating Patients With Locally Advanced, Metastatic, or Recurrent Soft Tissue Sarcoma or Bone Sarcoma",
      "status": "COMPLETED",
      "last_update": "2015-07-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "MOTESANIB": {
    "n": 1,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 1,
    "trials": [
     {
      "nct": "NCT02011126",
      "title": "Imetelstat Sodium in Treating Younger Patients With Relapsed or Refractory Solid Tumors",
      "status": "WITHDRAWN",
      "last_update": "2018-08-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "PALBOCICLIB": {
    "n": 7,
    "n_observational": 0,
    "n_active": 2,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT01291017",
      "title": "Cyclin Dependent Kinase (CDK)4/6 Inhibitor, PD0332991 in Advanced Non-small Cell Lung Cancer NSCLC.",
      "status": "COMPLETED",
      "last_update": "2016-05-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01320592",
      "title": "PD0332991/Paclitaxel in Advanced Breast Cancer",
      "status": "COMPLETED",
      "last_update": "2020-04-08",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03155620",
      "title": "Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03242382",
      "title": "Trial of Palbociclib in Second Line of Advanced Sarcomas With CDK4 Overexpression.",
      "status": "UNKNOWN",
      "last_update": "2024-01-23",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03526250",
      "title": "Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial)",
      "status": "COMPLETED",
      "last_update": "2026-04-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03709680",
      "title": "Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-01-14",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04129151",
      "title": "Palbociclib + Ganitumab In Ewing Sarcoma",
      "status": "TERMINATED",
      "last_update": "2024-08-01",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "PAZOPANIB": {
    "n": 6,
    "n_observational": 0,
    "n_active": 1,
    "n_withdrawn": 1,
    "trials": [
     {
      "nct": "NCT06239272",
      "title": "NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)",
      "status": "RECRUITING",
      "last_update": "2026-08-03",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01130623",
      "title": "A Phase I Study of Pazopanib as a Single Agent for Children With Refractory Solid Tumors",
      "status": "WITHDRAWN",
      "last_update": "2017-07-02",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01532687",
      "title": "Gemcitabine With or Without Pazopanib in Treating Patients With Refractory Soft Tissue Sarcoma",
      "status": "COMPLETED",
      "last_update": "2021-09-27",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01759303",
      "title": "Study of Pazopanib in the Treatment of Osteosarcoma Metastatic to the Lung",
      "status": "TERMINATED",
      "last_update": "2021-04-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02180867",
      "title": "Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery",
      "status": "COMPLETED",
      "last_update": "2026-06-17",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02357810",
      "title": "Pazopanib Hydrochloride and Topotecan Hydrochloride in Treating Patients With Metastatic Soft Tissue and Bone Sarcomas",
      "status": "COMPLETED",
      "last_update": "2022-06-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "RAMUCIRUMAB": {
    "n": 1,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT00428272",
      "title": "HGS-ETR2 to Treat Children With Solid Tumors",
      "status": "TERMINATED",
      "last_update": "2019-12-17",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "REGORAFENIB": {
    "n": 10,
    "n_observational": 0,
    "n_active": 6,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT04055220",
      "title": "Efficacy and Safety of Regorafenib as Maintenance Therapy After First-line Treatment in Patients With Bone Sarcomas",
      "status": "RECRUITING",
      "last_update": "2026-02-17",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04698785",
      "title": "Efficacy of Regorafenib Combined With Best Supportive Care as Maintenance Treatment in High Grade Bone Sarcomas Patients",
      "status": "RECRUITING",
      "last_update": "2026-02-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02048371",
      "title": "SARC024: A Blanket Protocol to Study Oral Regorafenib in Patients With Selected Sarcoma Subtypes",
      "status": "COMPLETED",
      "last_update": "2023-11-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02085148",
      "title": "A Phase I Dose Finding Study in Children With Solid Tumors Recurrent or Refractory to Standard Therapy",
      "status": "COMPLETED",
      "last_update": "2024-04-22",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02389244",
      "title": "A Phase II Study Evaluating Efficacy and Safety of Regorafenib in Patients With Metastatic Bone Sarcomas",
      "status": "COMPLETED",
      "last_update": "2026-07-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04803877",
      "title": "SARC038: Phase 2 Study of Regorafenib and Nivolumab in Osteosarcoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-10-31",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05395741",
      "title": "Regorafenib in Patients With Refractory Primary Bone Tumors",
      "status": "COMPLETED",
      "last_update": "2026-08-21",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05830084",
      "title": "Phase Ib / Regorafenib With Conventional Chemotherapy/Newly Diagnosed Patients/ Multimetastatic Ewing Sarcoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-01-06",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06041490",
      "title": "Adjuvant Therapy for High-risk Hepatocellular Carcinoma Post Liver Transplantation",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2023-09-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06820957",
      "title": "Testing a New Combination of Anti-cancer Drugs in Patients Newly Diagnosed With Ewing Sarcoma Who Have Cancer That Has Spread to Other Parts of the Body",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-21",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "ROBATUMUMAB": {
    "n": 2,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT00617890",
      "title": "A Study to Determine the Activity of Robatumumab (SCH 717454) in Participants With Relapsed Osteosarcoma or Ewing's Sarcoma (MK-7454-002/P04720)",
      "status": "TERMINATED",
      "last_update": "2018-08-23",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00960063",
      "title": "A Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Pediatric Participants With Advanced Solid Tumors (P05883, MK-7454-006)",
      "status": "TERMINATED",
      "last_update": "2018-08-27",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "SORAFENIB": {
    "n": 8,
    "n_observational": 0,
    "n_active": 2,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT07787429",
      "title": "Evaluation of the Safety and Efficacy of Mifamurtide Versus Standard Treatment With Sorafenib in Patients With High-risk Osteosarcoma",
      "status": "RECRUITING",
      "last_update": "2026-08-26",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00330421",
      "title": "Sorafenib in Treating Patients With Soft Tissue Sarcomas (Extremity Sarcoma Closed to Entry as of 5/30/07)",
      "status": "COMPLETED",
      "last_update": "2014-04-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00880542",
      "title": "Sorafenib and Ifosfamide in Treating Patients With High-Grade Soft Tissue Sarcoma or Bone Sarcoma That Can Be Removed by Surgery",
      "status": "TERMINATED",
      "last_update": "2020-08-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00889057",
      "title": "Sorafenib in Relapsed High Grade Osteosarcoma",
      "status": "COMPLETED",
      "last_update": "2013-03-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01518413",
      "title": "Dose Escalation Study of Sorafenib and Irinotecan Combination Therapy in Pediatric Patients With Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2015-02-27",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01804374",
      "title": "Phase II Open Label, Non-randomized Study of Sorafenib and Everolimus in Relapsed and Non-resectable Osteosarcoma",
      "status": "COMPLETED",
      "last_update": "2015-06-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02711007",
      "title": "Apatinib for Advanced Osteosarcoma After Failure of Standard Multimodal Therapy",
      "status": "COMPLETED",
      "last_update": "2018-04-23",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06041490",
      "title": "Adjuvant Therapy for High-risk Hepatocellular Carcinoma Post Liver Transplantation",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2023-09-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "SUNITINIB": {
    "n": 4,
    "n_observational": 0,
    "n_active": 2,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT03900793",
      "title": "Losartan + Sunitinib in Treatment of Osteosarcoma",
      "status": "RECRUITING",
      "last_update": "2026-09-01",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07477457",
      "title": "A Study of Gefitinib, Trametinib, Disulfiram, and Sunitinib in Addition to Standard Chemotherapy in People With Osteosarcoma",
      "status": "RECRUITING",
      "last_update": "2026-03-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00474994",
      "title": "Sunitinib in Treating Patients With Metastatic, Locally Advanced, or Locally Recurrent Sarcomas",
      "status": "COMPLETED",
      "last_update": "2016-01-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03277924",
      "title": "Trial of Sunitinib and/or Nivolumab Plus Chemotherapy in Advanced Soft Tissue and Bone Sarcomas",
      "status": "COMPLETED",
      "last_update": "2024-08-13",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "SUNITINIB MALATE": {
    "n": 4,
    "n_observational": 0,
    "n_active": 2,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT03900793",
      "title": "Losartan + Sunitinib in Treatment of Osteosarcoma",
      "status": "RECRUITING",
      "last_update": "2026-09-01",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07477457",
      "title": "A Study of Gefitinib, Trametinib, Disulfiram, and Sunitinib in Addition to Standard Chemotherapy in People With Osteosarcoma",
      "status": "RECRUITING",
      "last_update": "2026-03-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00474994",
      "title": "Sunitinib in Treating Patients With Metastatic, Locally Advanced, or Locally Recurrent Sarcomas",
      "status": "COMPLETED",
      "last_update": "2016-01-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03277924",
      "title": "Trial of Sunitinib and/or Nivolumab Plus Chemotherapy in Advanced Soft Tissue and Bone Sarcomas",
      "status": "COMPLETED",
      "last_update": "2024-08-13",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "SURUFATINIB": {
    "n": 4,
    "n_observational": 0,
    "n_active": 2,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT05093322",
      "title": "A Study of Surufatinib in Combination With Gemcitabine in Pediatric, Adolescent, and Young Adult Patients With Recurrent or Refractory Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2024-06-07",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05106777",
      "title": "Surufatinib in Patients With Osteosarcoma and Soft Tissue Sarcoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-06-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05590572",
      "title": "A Study of Sulfatinib on Relapsed or Refractory Drug Resistant Osteosarcoma",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2022-10-21",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05926492",
      "title": "A Clinical Study of Surufatinib Combined With Chemotherapy as Neoadjuvant Treatment in Osteosarcoma",
      "status": "UNKNOWN",
      "last_update": "2024-04-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "TRASTUZUMAB": {
    "n": 3,
    "n_observational": 0,
    "n_active": 1,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT04616560",
      "title": "Trastuzumab Deruxtecan (DS-8201a) for the Treatment of Recurrent or Refractory Osteosarcoma, Wilms Tumor, and Desmoplastic Small Round Cell Tumor",
      "status": "RECRUITING",
      "last_update": "2026-09-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00005033",
      "title": "Trastuzumab in Treating Patients With Recurrent Osteosarcoma",
      "status": "COMPLETED",
      "last_update": "2013-06-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00023998",
      "title": "Chemotherapy With or Without Trastuzumab in Treating Patients With Metastatic Osteosarcoma",
      "status": "COMPLETED",
      "last_update": "2013-02-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "TRASTUZUMAB DERUXTECAN": {
    "n": 1,
    "n_observational": 0,
    "n_active": 1,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT04616560",
      "title": "Trastuzumab Deruxtecan (DS-8201a) for the Treatment of Recurrent or Refractory Osteosarcoma, Wilms Tumor, and Desmoplastic Small Round Cell Tumor",
      "status": "RECRUITING",
      "last_update": "2026-09-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "TRILACICLIB": {
    "n": 3,
    "n_observational": 0,
    "n_active": 2,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT06699472",
      "title": "A Prospective, Randomized, Controlled Clinical Study on the Prevention of Chemotherapy Related Myelosuppression in Patients with Ewing's Sarcoma Using Trilaciclib",
      "status": "RECRUITING",
      "last_update": "2024-11-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06714383",
      "title": "Trilaciclib Combing Chemotherapy in the Neoadjuvant Treatment of Osteosarcoma",
      "status": "RECRUITING",
      "last_update": "2024-12-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06217003",
      "title": "Trilaciclib Combined With Chemotherapy for Perioperative Treatment of Osteosarcoma",
      "status": "UNKNOWN",
      "last_update": "2024-01-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "VATALANIB": {
    "n": 1,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT02711007",
      "title": "Apatinib for Advanced Osteosarcoma After Failure of Standard Multimodal Therapy",
      "status": "COMPLETED",
      "last_update": "2018-04-23",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     }
    ]
   }
  }
 }
}